NZ774113A - Dp antagonist - Google Patents

Dp antagonist

Info

Publication number
NZ774113A
NZ774113A NZ774113A NZ77411319A NZ774113A NZ 774113 A NZ774113 A NZ 774113A NZ 774113 A NZ774113 A NZ 774113A NZ 77411319 A NZ77411319 A NZ 77411319A NZ 774113 A NZ774113 A NZ 774113A
Authority
NZ
New Zealand
Prior art keywords
receptor
pharmaceutically acceptable
general formula
acceptable salt
compound represented
Prior art date
Application number
NZ774113A
Other languages
English (en)
Inventor
Atsushi Naganawa
Keisuke Hanada
Masaki Asada
Satonori Higuchi
Yasuhiro Takeda
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of NZ774113A publication Critical patent/NZ774113A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Auxiliary Devices For Music (AREA)
NZ774113A 2018-09-20 2019-09-19 Dp antagonist NZ774113A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018175758 2018-09-20
PCT/JP2019/036725 WO2020059790A1 (ja) 2018-09-20 2019-09-19 Ｄｐアンタゴニスト

Publications (1)

Publication Number Publication Date
NZ774113A true NZ774113A (en) 2024-09-27

Family

ID=69888481

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ774113A NZ774113A (en) 2018-09-20 2019-09-19 Dp antagonist

Country Status (17)

Country Link
US (3) US11319296B2 (enExample)
EP (1) EP3854781B1 (enExample)
JP (2) JP7021709B2 (enExample)
KR (2) KR102425709B1 (enExample)
CN (1) CN112739680A (enExample)
AU (1) AU2019341082A1 (enExample)
BR (1) BR112021005260A2 (enExample)
CA (1) CA3113210A1 (enExample)
ES (1) ES2982217T3 (enExample)
IL (2) IL310383A (enExample)
MX (1) MX2021003131A (enExample)
NZ (1) NZ774113A (enExample)
PH (1) PH12021550549A1 (enExample)
SG (1) SG11202102566YA (enExample)
TW (2) TWI822457B (enExample)
WO (1) WO2020059790A1 (enExample)
ZA (1) ZA202101887B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102425709B1 (ko) * 2018-09-20 2022-07-28 오노 야꾸힝 고교 가부시키가이샤 Dp 길항제
TW202146394A (zh) * 2020-03-19 2021-12-16 日商小野藥品工業股份有限公司 苯乙酸化合物之結晶
JP2024016311A (ja) * 2020-12-24 2024-02-07 小野薬品工業株式会社 Ｅｐ２アンタゴニスト

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63159342A (ja) 1985-04-03 1988-07-02 Yamanouchi Pharmaceut Co Ltd 新規カルボン酸化合物
US4994479A (en) * 1985-04-03 1991-02-19 Yamanouchi Pharmaceutical Co., Ltd. Phenylene derivatives and anti-allergic use thereof
NZ535309A (en) * 2002-03-19 2006-05-26 Ono Pharmaceutical Co Carboxylic acid compounds and drugs containing the compounds as the active ingredient
WO2005028455A1 (ja) * 2003-09-17 2005-03-31 Ono Pharmaceutical Co., Ltd. カルボン酸化合物およびそれらを有効成分として含有する医薬組成物
WO2005080367A1 (en) * 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
US7803786B2 (en) 2004-06-17 2010-09-28 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions and related methods of use
TWI410410B (zh) * 2007-08-10 2013-10-01 Ono Pharmaceutical Co Phenylacetic acid compounds
MX2014003386A (es) 2011-09-26 2014-06-23 Grünenthal GmbH Derivados de metansulfonamida sustituidos con amina como ligandos del receptor de vanilloide.
EP3558978A1 (en) 2016-12-20 2019-10-30 GlaxoSmithKline Intellectual Property Development Limited Modulators of indoleamine 2,3-dioxygenase
JP6533249B2 (ja) 2017-04-21 2019-06-19 山佐株式会社 遊技機用基板ケースの取り付け構造及び遊技機
CN110785408A (zh) 2017-06-28 2020-02-11 葛兰素史克知识产权开发有限公司 吲哚胺2,3-双加氧酶的调节剂
KR102425709B1 (ko) * 2018-09-20 2022-07-28 오노 야꾸힝 고교 가부시키가이샤 Dp 길항제

Also Published As

Publication number Publication date
IL281433A (en) 2021-04-29
WO2020059790A1 (ja) 2020-03-26
CA3113210A1 (en) 2020-03-26
JPWO2020059790A1 (ja) 2021-09-02
ZA202101887B (en) 2022-10-26
JP2022058610A (ja) 2022-04-12
JP7021709B2 (ja) 2022-02-17
TW202308986A (zh) 2023-03-01
KR20220107330A (ko) 2022-08-02
ES2982217T3 (es) 2024-10-15
US20220204468A1 (en) 2022-06-30
CN112739680A (zh) 2021-04-30
TW202023535A (zh) 2020-07-01
KR20210065944A (ko) 2021-06-04
IL310383A (en) 2024-03-01
TWI784199B (zh) 2022-11-21
KR102425709B1 (ko) 2022-07-28
EP3854781B1 (en) 2024-05-22
BR112021005260A2 (pt) 2021-06-15
SG11202102566YA (en) 2021-04-29
MX2021003131A (es) 2021-05-14
AU2019341082A1 (en) 2021-04-15
JP7338711B2 (ja) 2023-09-05
TWI822457B (zh) 2023-11-11
US20250042870A1 (en) 2025-02-06
US11319296B2 (en) 2022-05-03
EP3854781A4 (en) 2022-02-23
US20220033371A1 (en) 2022-02-03
EP3854781A1 (en) 2021-07-28
PH12021550549A1 (en) 2022-02-14

Similar Documents

Publication Publication Date Title
ZA202108745B (en) Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
EP4529954A3 (en) Thrb receptor agonist compound and preparation method and use thereof
PH12021551196A1 (en) 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
PH12022551359A1 (en) Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
PH12020550683A1 (en) Novel bradykinin b2 receptor antagonists
CA2912921C (en) Pyrazole compounds as modulators of fshr and uses thereof
NZ774113A (en) Dp antagonist
PH12021553155A1 (en) Ep2 antagonist
GEP20257716B (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
BR112018005589A2 (pt) “composto, composição farmaceuticamente aceitável, e, uso de um composto”
ZA202002762B (en) Benzimidazole derivatives and their uses
EP4494705A3 (en) Non-peptide oxytocin receptor agonists
CR20240353A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
MX2021003901A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
MX2021009082A (es) Compuestos quimicos.
MX381768B (es) Combinación de antagonistas puros del receptor 5-ht6 con inhibidores de la acetilcolinesterasa.
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
GEP20257771B (en) Compounds and compositions as sppl2a inhibitors
MX2022004215A (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4.
AU2016407426A1 (en) Triple combination of pure 5-HT6 receptor antagonists, Acetylcholinesterase inhibitors and NMDA receptor antagonist
MY189372A (en) Indole derivatives
GEP20247629B (en) Alcohol derivatives as kv7 potassium channel openers
MX2021004471A (es) Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1.
MX2024005997A (es) Antagonistas del receptor de adenosina.